Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
BridgeBio Oncology Therapeutics, Inc (BBOT) had Weighted-Average Shares Outstanding (Diluted) of 31.14M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-134.04M |
|
-- |
|
-- |
|
$145.82M |
|
$-145.82M |
|
$11.78M |
|
$-134.04M |
|
$-134.04M |
|
$-134.04M |
|
$-134.04M |
|
$-134.04M |
|
$-134.04M |
|
$-145.82M |
|
$-145.21M |
|
31.14M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
31.14M |
$-4.30 |
|
$-4.30 |
|
| Balance Sheet Financials | |
$432.40M |
|
$0.96M |
|
$15.98M |
|
$448.38M |
|
$35.04M |
|
-- |
|
$2.24M |
|
$37.28M |
|
$411.10M |
|
$411.10M |
|
$411.10M |
|
79.99M |
|
| Cash Flow Statement Financials | |
$-113.89M |
|
$73.33M |
|
$383.40M |
|
$30.98M |
|
$373.82M |
|
$342.84M |
|
$5.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-114.50M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-32.61% |
|
-32.61% |
|
-29.90% |
|
-32.61% |
|
$5.14 |
|
$-3.68 |
|
$-3.66 |
|